A Phase IIa Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 After 3 Weeks of Treatment in Patients With Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN).

Trial Profile

A Phase IIa Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 After 3 Weeks of Treatment in Patients With Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN).

Suspended
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2012

At a glance

  • Drugs AZD 1386 (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms AVANT
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Mar 2012 This trial is recruiting in France and discontinued in United Kingdon and Denmark.
    • 01 Oct 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 17 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top